Common Contracts
2 similar Agreement Concerning Joint contracts
Agreement Concerning Joint Research of Ophthalmic drugAgreement Concerning Joint • April 12th, 2023
March 22,2006—CytoPathfinder, Inc.(headquartered in Tokyo, Shinagawa, Japan, CEO: Yoshiji Fujita) and Santen Pharmaceutical Co., Ltd. (headquartered in Osaka, Japan, President and CEO: Takakazu Morita) announced that they have signed a three-year research agreement to jointly search target molecule for ophthalmology drug discovery and apply CytoPathfinder’s cubic liquid crystal technology to ophthalmic drug formulation.
Agreement Concerning Joint Research of Ophthalmic drugAgreement Concerning Joint • September 10th, 2021
March 22,2006—CytoPathfinder, Inc.(headquartered in Tokyo, Shinagawa, Japan, CEO: Yoshiji Fujita) and Santen Pharmaceutical Co., Ltd. (headquartered in Osaka, Japan, President and CEO: Takakazu Morita) announced that they have signed a three-year research agreement to jointly search target molecule for ophthalmology drug discovery and apply CytoPathfinder’s cubic liquid crystal technology to ophthalmic drug formulation.
